Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines. Its pipeline includes OCU400, a gene therapy for inherited retinal diseases like retinitis pigmentosa (Phase 3) and Leber congenital amaurosis (Phase 1/2). It also has OCU410 for dry age-related macular degeneration (Phase 1/2), OCU410ST for Stargardt disease (Phase 1/2), and OCU200 for diabetic macular edema and wet AMD. Additionally, Ocugen is developing NeoCart for knee cartilage repair and vaccine candidates OCU500 (COVID-19), OCU510 (seasonal flu), and OCU520 (combination flu/COVID-19). The company collaborates with the National Institute of Allergy and Infectious Diseases and has a strategic partnership with CanSino Biologics for manufacturing.

Ocugen, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol OCGN. Its shares are traded in US Dollars (USD), as the company is headquartered in the United States. The NasdaqCM is a US-based stock exchange that lists early-stage and growth companies, providing Ocugen with access to public capital markets to fund its research and development activities.

Ocugen operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing advanced therapies such as gene therapies, cell therapies, biologics, and vaccines. Biotechnology companies like Ocugen use living organisms or their components to create medical treatments, often targeting diseases with high unmet medical needs, such as inherited retinal diseases, age-related macular degeneration, and infectious diseases like COVID-19 and influenza.

Ocugen, Inc. is headquartered in Malvern, Pennsylvania, United States. The company primarily serves the US market, as indicated by its US-based operations and listing on a US exchange. Its pipeline addresses diseases prevalent in developed markets, such as retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy. While its collaborations, such as with CanSino Biologics in China, suggest potential global reach, the company's focus remains on developing therapies for patients in the United States and other regions where these conditions are common.

Ocugen's pipeline includes several key product candidates. OCU400 is a novel gene therapy for inherited retinal diseases, currently in Phase 3 for retinitis pigmentosa and Phase 1/2 for Leber congenital amaurosis. OCU410 targets dry age-related macular degeneration (Phase 1/2), and OCU410ST targets Stargardt disease (Phase 1/2). OCU200 is a recombinant fusion protein for diabetic macular edema, diabetic retinopathy, and wet AMD. NeoCart is an autologous chondrocyte-derived neocartilage for knee cartilage repair. In vaccines, OCU500 is a COVID-19 vaccine, OCU510 a seasonal quadrivalent flu vaccine, and OCU520 a combination flu/COVID-19 vaccine. The company also has a strategic partnership with CanSino Biologics for manufacturing its modifier gene therapy products.